Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Production / Operations Routine +

Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness

Certification Milestone Validates Platform Maturity But Revenue Visibility Remains Constrained

By The Northwire Desk — AI Analysis Apr 14, 2026 · 09:51 SEGN · 0.335 Seegnal Inc.
Executive Summary
  • Seegnal Inc.'s Israeli subsidiary, Seegnal eHealth Ltd., received the Gold Mark from the Standards Institution of Israel on April 14, 2026.
  • The certification recognizes excellence in management systems, processes, and product lifecycles for commercialization readiness.
  • Qualification required holding three specific quality certifications: ISO 13485:2016 (Medical Devices), ISO 27799 (Health Information Security), and ISO 27001:2022 (Information Security).
  • The news serves as an operational update confirming enterprise-grade compliance standards.
  • No new revenue figures, contract values, or specific customer acquisition numbers were disclosed in this release.
Material Impact
  • The Gold Mark certification is a validation of existing claims rather than a catalyst for immediate revenue growth.
  • It supports the February 2026 announcement regarding the expansion at Tel Aviv Sourasky Medical Center by confirming regulatory and security compliance required for large-scale hospital deployments.
  • The news aligns with the January 2026 presentation on real-world evidence, reinforcing the company's narrative of clinical safety and governance.
  • Given the stock price volatility seen in September 2025 (dropping from $1.00 to $0.21), this certification provides stability but lacks the magnitude to be classified as a "Game Changer."
  • The market likely anticipated compliance milestones given the new CEO's focus on enterprise governance and US expansion mentioned in December 2025.
SEGN · Price
Company Overview
  • Company: Seegnal Inc., operating through Israeli subsidiary Seegnal eHealth Ltd.
  • Flagship Project: Prescription Intelligence Platform, a SaaS solution providing real-time, patient-specific medication decision support using explainable AI.
  • Platform Scale: Claims to process >400,000 prescriptions per day with >174 million total prescriptions analyzed and >20,000 clinicians currently using the system.
  • Geographic Reach: Deployed in Israel (national standard), UAE, United Kingdom, United States, and Poland.
  • Product Suite: Includes core decision support and newer modules like "MetricsGuard" for patient-specific risk detection (e.g., hypoglycemia alerts).
Read the original news release →

More from Seegnal Inc.

Jun 25, 2026 · 08:30

Israeli med-tech SaaS expands domestic footprint while navigating severe liquidity constraints and unproven U.S. commercialization.

Other Jun 19, 2026 · 08:30

Seegnal Successfully Initiates First U.S. Pilot Program

Production / Operations Jun 05, 2026 · 08:30

Seegnal Inc. - AI-Driven Prescription Intelligence Platform for Medication Safety

M&A / Property Jun 02, 2026 · 17:00

Seegnal Raises $1.3M at a Discount to Fund Burn Rate as Filing Delays and Going Concern Risks Mount

Financings May 19, 2026 · 08:30

Seegnal Eyes U.S. Expansion Amid Regulatory Filing Overhang

Other May 06, 2026 · 17:00

Filing Default Lingers as Seegnal Pushes Audit Deadline

Regulatory